Abstract: Chemotherapy are the main treatment for advanced or recurrent endometrial cancer. The role of chemotherapy in the high-risk patient is currently the focus of the researchers. Among the current Gynaecologic Oncology Group（GOG） trials in endometrial cancer treatment，GOG209 comparing carboplatin and paclitaxel （TcP） with the triplet of doxorubicin，paclitaxel and cisplatin（TAP） is the most anticipated study and may be challenge the current standard regimen of TAP. Radiation plus chemotherapy significantly improved overall survival（OS） and progression-free survival（PFS） for patients with early endometrial cancer at high risk for micrometastases. Chemotherapy， interval radiation and further chemotherapy（CRC） may be the most favorable sequence given in the improved overall survival in patients with endometrial cancer. The toxicity of cytotoxic agents should not be ignored. The sequential doublet therapy with carboplatin/paclitaxel and carboplatin/doxorubicin are strategies that may be considered to reduce drug toxicity.

Key words: Endometrial neoplasms, Antineoplastic combined chemotherapy protocols, Controlled clinical trial, Therapy, Drug therapy